Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.

Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Corporate Finance / M&A

In Corporate Finance, Bioscience Valuation advises companies and investors on growth finance and project finance transactions.

Bioscience Valuation maintains a strong network of private individuals, family offices and institutional investors that are interested in significant investment opportunities. Within this network Bioscience Valuation is able to raise private equity, debt capital and mezzanine financing. Prior to accepting a private placement mandate, we conduct our own due diligence of the financing target.

In M&A, Bioscience Valuation advises management and shareholders on the various types of M&A transactions:

  • sell-side advisory,
  • entrepreneurial successions,
  • buy-side advisory,
  • management buy-out / management buy-in.

Furthermore, Bioscience Valuation provides in-depth advisory at the various steps of an M&A transaction process:

  • design of transaction structure,
  • advice on disposal/acquisition strategy and tactical issues addressing issues such as control, earn outs,
  • taxation, dividend policy, executive lock ups,
  • compilation of documentation and any associated documents,
  • company valuation,
  • contact with potential buyers/potential targets,
  • coordination of and assistance with the due diligence process,
  • assistance in the negotiations with potential buyers/sellers,
  • review of commercial aspects of the contractual documentation,
  • assistance with the preparation of presentations for the Board of directors and shareholders,
  • project management and coordination of involved parties.





This website uses cookies to ensure you get the best experience on our website.
Privacy Policy